Asia-Pacific
Matthew Swinn, who leads the firm’s IP practice, discusses why Mallesons is well-placed to remain a major IP force
Leighton Cassidy Legal hopes to leverage its founder's international experience and provide clients with a rare chance to receive litigation and prosecution under one umbrella
In the final part of a series on challenging patent invalidation decisions in China, lawyers at Spruson & Ferguson and Marshall Gerstein share how courts adjudicate appeals
Mohit and Sidhant Goel decided not to pursue an interim injunction application so that their client, Communications Components Antenna, could benefit from a fast-track trial
Sponsored
Sponsored
-
Sponsored by Tilleke & GibbinsLinh Thi Mai Nguyen and Chi Lan Dang of Tilleke & Gibbins outline the IP changes that will come into force in 2023, and share their opinion on the merits and drawbacks of each -
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law summarises the key points of the Korean Intellectual Property Office’s updated guidance regarding artificial intelligence patent filings as the intellectual property world adapts to a growing area
-
Sponsored by FB RiceJacqueline Warner and Marcus Caulfield of FB Rice explain the significance of common general knowledge (CGK) in the patentability of inventions in Australia and the evidentiary processes that are adopted as a result
-
Sponsored by ABE & PartnersTakanori Abe of ABE & Partners examines the Tokyo District Court and Intellectual Property High Court rulings on Ricoh’s claim that Ds Japan infringed its patent rights regarding toner cartridges for printers
-
Sponsored by Saint Island International Patent & Law OfficesFrank Liu of Saint Island International Patent & Law Offices describes the progress of a significant patent infringement case in Taiwan and the extended involvement of the Intellectual Property and Commercial Court
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees
